Sample Submission Guidelines
Build Molecular Evidence for ASO and siRNA Candidate Decisions
ASO and siRNA projects often begin with a simple question: did the candidate reduce the intended target? For early screening, that answer may be enough. For lead selection, mechanism work, or safety-related research, your team usually needs a broader molecular view.
We help you look beyond the target gene. With transcriptomics, small RNA-related profiling, targeted validation support, and custom bioinformatics, our team helps you understand how an ASO or siRNA candidate changes the system around the target.
That means you can examine whether downstream pathways shift as expected, whether non-target transcripts change, and whether immune, inflammatory, stress, or toxicity-associated signatures appear in the tested model.
From Gene Silencing to Interpretable Omics Evidence
Target knockdown is only one part of the story. One candidate may reduce the intended transcript but create broad expression shifts elsewhere. Another may show moderate knockdown but produce a cleaner pathway profile. Omics data helps bring those differences into view.
Our ASO and siRNA drug development omics solution connects candidate design, sample grouping, sequencing data, and interpretation-ready outputs. We focus on helping your team answer not only "what changed?" but also "which changes matter for the next research decision?"
Where This Solution Fits in Discovery and Safety Research
This solution is useful when your team needs molecular evidence for candidate screening, target validation, off-target review, dose or time comparison, model selection, or safety-related mechanism exploration.
We can support in vitro studies, cell model studies, tissue-based studies, animal-model research, and multi-condition comparison designs. The final workflow depends on your modality, sample type, species, candidate number, dose groups, time points, and biological endpoint.
What CD Genomics Helps You Evaluate
- Whether ASO or siRNA treatment produces the expected target response
- Which downstream genes and pathways change after treatment
- Whether transcriptome-wide off-target signals are present
- Whether immune, inflammatory, stress, or toxicity-associated pathways are activated
- How candidates compare across dose, time point, tissue, or model
- Which genes, pathways, or signatures should be prioritized for follow-up validation
Our Service Capabilities for ASO / siRNA R&D Support
We support ASO and siRNA research as a project workflow, not as a single isolated assay. Your team may come to us with extracted RNA, treated cell pellets, tissue samples, a candidate panel, or an existing experimental design. We help map those inputs to the most useful sequencing and analysis plan.
The final goal is a data package your team can actually use: QC summaries, expression matrices, differential expression results, pathway outputs, figures, candidate comparison tables, and method notes that can be reviewed by biology, pharmacology, safety, and bioinformatics teams.
Transcriptomics for Knockdown and Pathway Response
RNA-Seq is often the main data layer for ASO and siRNA response profiling. It can show whether the intended target is reduced, how downstream genes respond, and whether treatment creates broader transcriptional shifts.
For ASO and siRNA studies, transcriptomics can be used to compare treated versus control groups, multiple candidates, dose levels, time points, tissues, or cell models. We also help identify genes and pathways that may deserve targeted validation.
Small RNA and miRNA-Related Profiling for siRNA Research
For siRNA studies, small RNA biology can become important when the project involves seed-region effects, miRNA-like regulation, endogenous small RNA perturbation, or RNA regulatory shifts. In those cases, Small RNA Sequencing may add a useful layer.
This module is not required for every project. We usually consider it when the research question involves small RNA abundance, regulatory RNA changes, miRNA-related pathways, or a deeper review of siRNA-associated molecular response.
Targeted Validation and Candidate Comparison Support
After transcriptome-wide profiling, many teams need a shorter list of genes or pathways for follow-up. CD Genomics can help prepare candidate lists for targeted validation based on differential expression, pathway relevance, off-target concern, immune-response signatures, or project-specific biology.
For focused follow-up, Targeted RNA Sequencing may be useful when your team wants to track selected transcripts across additional samples, candidate designs, or study conditions.
Custom Bioinformatics for Off-Target and Safety-Related Signals
ASO and siRNA studies often need more than a standard differential expression table. Our Bioinformatics Services help connect expression changes with candidate design, treatment group, pathway biology, dose, time point, and model-specific response.
We can support custom review of siRNA seed-related patterns, ASO hybridization-related candidate genes, immune pathway enrichment, inflammatory signaling, stress response, tissue response, and cross-candidate comparison when these analyses fit the study design.
Research Questions This Solution Can Address
Different stages of ASO and siRNA research require different kinds of evidence. Early discovery may focus on target reduction. Candidate screening may focus on ranking. Safety-related research may focus on unwanted pathway activation or broad transcriptome disturbance.
We help translate those questions into a practical sequencing and analysis design.
| Research Question | Recommended Data Layer | Typical Output | How It Supports Your Decision |
|---|---|---|---|
| Is the intended target reduced? | RNA-seq or targeted RNA validation | Target expression profile, differential expression table | Confirms whether the candidate produces the expected transcript-level effect |
| Does the pathway response match the expected biology? | RNA-seq with pathway enrichment | GO / KEGG / pathway enrichment, heatmap, pathway plots | Shows whether target reduction is connected to a relevant biological response |
| Are there transcriptome-wide off-target changes? | RNA-seq with off-target-focused bioinformatics | Expression shift review, affected gene sets, candidate off-target list | Helps distinguish intended biology from broader unintended expression changes |
| Are immune or inflammatory pathways activated? | RNA-seq with pathway-focused analysis | Immune pathway review, inflammatory gene panels, enrichment results | Supports interpretation of safety-related molecular response in the tested model |
| Which candidate looks cleaner across endpoints? | Multi-candidate transcriptomics and comparison matrix | Candidate-by-endpoint ranking table | Helps compare knockdown, pathway response, off-target signal, and QC status together |
Is the Candidate Producing the Intended Knockdown Response?
We compare treated and control samples to measure target expression and downstream expression changes. This helps your team determine whether observed knockdown is consistent, biologically relevant, and worth extending into further study conditions.
Are There Transcriptome-Wide Off-Target Changes?
Transcriptome-wide profiling can reveal expression changes beyond the intended target. For siRNA, one concern is seed-mediated off-target regulation. For ASO, one concern is hybridization-dependent interaction with unintended transcripts. The analysis design should reflect the oligonucleotide type, sequence design, and study model.
Are Immune or Inflammatory Pathways Activated?
Some ASO and siRNA candidates may produce stress, immune, or inflammatory molecular signatures in specific models or treatment settings. RNA-seq can help identify whether these pathways are changing and which genes contribute to the signal.
How Do Dose, Time Point, Tissue, or Model Change the Response?
A single condition may not reveal the full response pattern. Dose-response or time-course transcriptomics can help separate early treatment effects, sustained pathway response, and condition-specific expression changes.
Workflow from Sample Intake to Reusable Data Package
Once your samples enter the project, we move through a combined service and technical workflow: project review, sample and metadata check, RNA quality control, library preparation, sequencing, primary data QC, bioinformatics analysis, report delivery, and follow-up interpretation.
This workflow is designed to protect sample-to-data traceability. At each stage, we check whether the data are ready for the next step and whether the final outputs will be useful for your internal review.
Project Intake and Endpoint Mapping
We begin by reviewing your ASO or siRNA modality, target gene, species, model, treatment groups, dose levels, time points, sample type, and intended endpoint. This helps us decide whether your project needs RNA-seq, small RNA sequencing, targeted RNA sequencing, custom bioinformatics, or a combined workflow.
We also clarify the comparison structure. Your project may compare treated versus untreated samples, multiple candidates against one control, several dose groups, different tissues, or time points after treatment.
Sample Planning and Group Design
Before sample submission, we review sample type, extraction status, estimated input amount, RNA integrity, storage condition, and metadata. For ASO and siRNA studies, metadata is especially important because interpretation depends on candidate ID, dose, exposure time, treatment condition, replicate group, tissue or cell model, and control type.
Clear metadata helps us build the analysis matrix correctly and reduces ambiguity when the results are interpreted.
RNA Quality Control and Library Preparation
After samples arrive, we assess RNA amount, concentration, purity, and integrity. Samples that meet the agreed project criteria move into library preparation.
For transcriptome profiling, the technical process may include RNA fragmentation or enrichment/depletion steps as appropriate, cDNA synthesis, adapter ligation or amplification, library QC, and sequencing. For small RNA sequencing, the workflow is adjusted to capture small RNA species and prepare size-appropriate libraries.
Library QC helps confirm whether the prepared libraries are suitable for sequencing before data generation begins.
Sequencing and Primary Data QC
Sequencing produces raw reads that are processed into clean data. Primary QC may include read quality review, adapter trimming, read length distribution, base quality, mapping or alignment summary, duplication review where relevant, and sample-level consistency checks.
These QC steps help identify technical issues before biological interpretation begins.
Differential Expression, Pathway Review, and Off-Target-Focused Analysis
After primary processing, we generate expression matrices and compare the planned sample groups. Differential expression analysis identifies genes that change between conditions. Pathway enrichment helps organize those changes into biological themes.
For ASO and siRNA studies, we can add focused analysis for off-target-related patterns, immune or inflammatory pathways, stress response, candidate comparison, dose trend, time trend, or tissue-specific response when the study design supports it.
Report Delivery and Follow-Up Interpretation
Your final package can include raw data, processed data, QC files, result tables, visualizations, pathway outputs, software or parameter notes, and a report. We aim to provide files that your internal team can reuse, inspect, and integrate with other project information.
After delivery, we can help your team review the structure of the outputs and identify which genes, pathways, or candidate-level signals may be useful for follow-up validation.
Sample Requirements and Study Design Inputs
Sample needs vary by sample type, extraction status, sequencing strategy, and study goal. The table below gives practical starting values for project discussion. Final input requirements should be confirmed before sample submission.
| Sample Type | Recommended Input | Quality Checks | Required Metadata | Notes |
|---|---|---|---|---|
| Total RNA for RNA-seq | ≥1 μg preferred; ≥100 ng may be reviewed for low-input workflows | Concentration, purity, integrity; RIN ≥7 preferred for high-quality RNA | Candidate ID, dose, time point, control, replicate, species, tissue/cell type | Best for transcriptome-wide knockdown and pathway response profiling |
| Cell pellets | ≥1 × 106 cells preferred | Cell status, storage condition, RNA extraction QC after processing | Treatment condition, candidate ID, exposure time, replicate group | Suitable when RNA extraction is included in the project workflow |
| Fresh frozen tissue | ≥30 mg preferred where available | RNA yield, purity, integrity, degradation risk | Tissue type, collection method, treatment group, dose, time point | Useful for tissue-response and safety-related molecular profiling |
| Small RNA sequencing sample | ≥1 μg total RNA preferred | Small RNA fraction suitability, total RNA quality, purity | siRNA design, treatment group, model, dose, time point | Consider when small RNA or miRNA-related response is central |
| Low-input or difficult samples | Case-by-case review required | Input amount, degradation, inhibitor risk, extraction method | Sample history, storage, collection method, biological grouping | We review feasibility before recommending a workflow |
Sample Types Commonly Used in ASO / siRNA Studies
Common starting materials include extracted RNA, cell pellets, treated cell models, fresh frozen tissues, and model-specific biological samples. For each sample type, we confirm extraction method, storage condition, expected RNA quality, and grouping metadata before project initiation.
Metadata That Improves Interpretation
For ASO and siRNA studies, metadata is not a formality. It directly affects interpretation. At minimum, please provide candidate ID, sequence or design group where appropriate, target gene, treatment group, dose, time point, control group, biological replicate, species, tissue or cell type, and any observed phenotype or assay endpoint.
Bioinformatics Analysis and Deliverables
Bioinformatics is central to this solution. Without it, ASO and siRNA sequencing data can become a long gene list without a clear decision path. We structure the analysis to help your team see target response, broad expression changes, pathway-level shifts, candidate differences, and follow-up priorities.
Minimum Deliverables
- Raw sequencing data
- Clean reads or processed reads
- Sequencing QC summary
- Alignment or mapping summary where applicable
- Gene expression matrix
- Differential expression table
- Volcano plot
- Heatmap or clustering plot
- PCA or sample relationship plot
- Pathway enrichment results
- Methods and parameter notes
- Analysis report
Optional Add-On Analysis Modules
- siRNA seed-region off-target enrichment review
- ASO hybridization-dependent off-target candidate review
- Dose-response expression trend analysis
- Time-course transcriptomic response analysis
- Immune or inflammatory pathway focused analysis
- Cross-candidate comparison matrix
- Tissue or cell-type response comparison
- Multi-omics integration when additional data are available
- Targeted validation candidate list for qPCR follow-up
Reusable Files for Internal Biology and Bioinformatics Teams
Your internal team may need more than a PDF report. We can provide analysis-ready tables and file outputs such as FASTQ files, count matrices, normalized expression matrices, differential expression tables, enrichment tables, QC summaries, pathway figures, and parameter notes.
These outputs help your biology team review candidate behavior, your bioinformatics team inspect the analysis structure, and your project team decide which findings should move into validation or additional experiments.
Choosing the Right Omics Strategy for Your ASO / siRNA Project
Not every project needs every assay. A strong study design starts with the decision your team needs to make. We help you select the most useful data layer based on modality, candidate stage, sample type, and risk question.
ASO vs siRNA: What Changes in Analysis Design
| Dimension | ASO Projects | siRNA Projects | Why It Matters |
|---|---|---|---|
| Main mechanism to consider | May involve RNase H-mediated degradation, splice modulation, or steric blocking depending on design | Usually involves RISC-mediated RNA interference through guide-strand targeting | The expected molecular readout depends on how the candidate acts on RNA |
| Primary readout | Target RNA reduction, splice or isoform effect, and downstream transcriptome response | Target mRNA knockdown and downstream expression response | Determines whether standard RNA-seq is sufficient or whether isoform or targeted follow-up is needed |
| Common off-target concern | Hybridization-dependent binding to unintended RNA transcripts | Seed-mediated or sequence-related transcriptome effects | Guides the off-target review strategy and bioinformatics focus |
| Safety-related molecular signals | Immune response, tissue response, chemistry-associated patterns, or unintended transcript reduction | Immune response, delivery-related response, seed-related expression shifts, or pathway perturbation | Helps determine whether pathway-focused analysis should be added |
| Useful data layers | RNA-seq, targeted validation, isoform-aware analysis when relevant, custom off-target review | RNA-seq, small RNA-related analysis, seed-region review, pathway analysis | Allows the workflow to match the modality rather than forcing one template on every project |
RNA-Seq vs Targeted Validation vs Small RNA Profiling
| Approach | Best Used When | Strength | Limitation | Typical Role in This Solution |
|---|---|---|---|---|
| RNA-seq | You need transcriptome-wide knockdown, pathway, and off-target information | Broad, discovery-friendly, useful for unexpected changes | Requires careful study design and bioinformatics interpretation | Main data layer for response profiling |
| Targeted RNA validation | You already know which genes or pathways need focused follow-up | Efficient for selected targets and larger follow-up panels | Does not capture broad unexpected transcriptome changes | Follow-up validation or candidate comparison |
| Small RNA sequencing | The project involves small RNA abundance, miRNA-like regulation, or siRNA-related RNA regulatory effects | Adds a small RNA layer that RNA-seq alone may not address | Not required for every ASO or siRNA project | Optional add-on for selected siRNA-focused designs |
| Time-course transcriptomics | You need to distinguish early response from sustained response | Shows response dynamics | Requires more samples and careful comparison structure | Useful for mechanism and response-duration studies |
| Multi-omics integration | Transcriptomic signals need to be connected with other molecular or phenotypic data | Provides a broader biological view | Needs clear endpoints and compatible data types | Optional for complex mechanism or safety-related research |
Selection Rules by Project Stage and Risk Type
- Use RNA-seq when transcriptome-wide response and off-target profiling are needed.
- Add small RNA or miRNA-related analysis when siRNA seed effects or RNA regulatory shifts are central.
- Add targeted validation when top genes or pathways need follow-up confirmation.
- Add dose-response or time-course design when response dynamics matter.
- Add multi-omics integration only when transcriptomic signals must be linked to additional biological layers.
- Keep the workflow modular; do not add assays that do not answer the project question.
References
- SeedMatchR: identify off-target effects mediated by siRNA seed regions in RNA-seq experiments
- Assessing Hybridization-Dependent Off-Target Risk for Therapeutic Oligonucleotides: Updated Industry Recommendations
- Evaluation of off-target effects of gapmer antisense oligonucleotides using human cells
- Preclinical Safety Assessment of Therapeutic Oligonucleotides
- Clinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics
Demo Results: What Your ASO / siRNA Omics Data May Show
The exact result pattern depends on your candidate, model, sample quality, and study design. The examples below show the types of outputs that can be included in an ASO and siRNA omics data package.
Knockdown and Pathway Response Overview
A volcano plot can show genes that are changed between treatment and control groups. A pathway enrichment panel can then group those genes into biological themes, such as target-associated pathways, immune signaling, stress response, metabolic response, or disease-relevant processes.
This helps your team move from a single target readout to a broader view of treatment response.
Off-Target Expression Shift Visualization
A heatmap, cumulative distribution plot, or seed-match-aware expression shift plot can help highlight whether a subset of genes shows broad downregulation or unexpected expression movement after treatment.
For siRNA studies, this can be useful when reviewing potential seed-mediated effects. For ASO studies, a focused review may look at candidate transcripts with sequence complementarity or relevant expression changes.
Candidate Ranking Summary
When multiple candidates are tested, a candidate-by-endpoint matrix can bring key signals together. For example, rows can represent candidates and columns can summarize target knockdown, pathway response, off-target signal, immune pathway activation, sample QC, and follow-up priority.
This format gives project teams a clearer view of which candidates may deserve further study.
FAQ
1. How can RNA-seq support ASO and siRNA candidate evaluation?
RNA-seq can show whether the intended target changes and how the broader transcriptome responds. For ASO and siRNA studies, this helps connect target modulation with pathway response, off-target review, immune-related signatures, and candidate comparison.
2. Can this solution help distinguish on-target response from off-target transcriptomic changes?
It can help your team review the pattern. We compare planned treatment groups, identify differentially expressed genes, review pathway behavior, and add off-target-focused analysis when supported by the candidate design and study structure. The result is a clearer molecular profile for follow-up research decisions.
3. When should we add small RNA sequencing to an siRNA project?
Small RNA sequencing is most useful when small RNA abundance, miRNA-like regulation, seed-region biology, or RNA regulatory shifts are part of the research question. It is not required for every siRNA project.
4. What sample information should we provide before project design?
Please provide sample type, species, target gene, ASO or siRNA candidate information, treatment group, dose, time point, control group, replicate number, tissue or cell model, and any known assay results. This information helps us recommend a suitable workflow.
5. Can CD Genomics compare multiple ASO or siRNA candidates?
Yes. We can support multi-candidate designs when the grouping structure is clear. Typical comparisons may include target knockdown, pathway response, transcriptome-wide expression shift, immune or inflammatory pathway signal, and QC status.
6. What deliverables will our internal team receive?
Depending on the project scope, deliverables may include raw data, processed reads, QC summaries, expression matrices, differential expression tables, enrichment results, figures, candidate comparison tables, method notes, and an analysis report.
7. Can immune or inflammatory pathway activation be reviewed from transcriptomics data?
Yes, if the study design and sample quality support the analysis. We can review immune-related genes, inflammatory pathways, stress response signatures, and enrichment results to help your team understand treatment-associated molecular response in the tested model.
8. Is targeted validation still needed after RNA-seq?
Often, yes. RNA-seq is useful for broad discovery and ranking. Targeted validation is useful when your team wants to confirm selected genes or pathways across more samples, conditions, or candidate designs.
9. Can this workflow support dose-response or time-course studies?
Yes. Dose-response and time-course designs can be built into the sample grouping structure. These designs are useful when your team needs to understand whether a response is dose-associated, transient, sustained, or model-specific.
10. How do we start a project discussion?
Share your modality, sample type, candidate number, species, model, dose groups, time points, and research endpoint. Our team can then help map your study goal to a sequencing and bioinformatics workflow.
Case Study: Detecting siRNA Seed-Mediated Off-Target Effects with RNA-Seq
This case is based on the open-access paper SeedMatchR: identify off-target effects mediated by siRNA seed regions in RNA-seq experiments.
Background
siRNA treatment is intended to reduce the expression of a target mRNA through guide-strand complementarity. However, the siRNA seed region can also behave in a miRNA-like way and affect unintended transcripts. This creates a practical challenge for siRNA candidate evaluation: a candidate may show target knockdown while also producing broader transcriptomic changes.
The SeedMatchR paper addressed this challenge by developing a workflow to detect and visualize seed-mediated off-target effects in RNA-seq experiments. The paper focused on connecting differential expression analysis with predicted seed matches so that researchers can examine whether genes with seed matches show cumulative expression shifts.
Methods
Input Data
- siRNA guide sequence
- Differential expression results table
- Species-specific GTF annotation
- Feature-specific DNA sequence set
Analysis Workflow
- Seed-region definition
- Predicted seed match annotation
- Gene-level expression comparison
- Expression distribution visualization
Output Review
- Seed match count annotation
- Genes with and without seed matches
- ECDF-based expression shift review
- Off-target pattern interpretation
The study introduced SeedMatchR as an R package that works with RNA-seq differential expression results. SeedMatchR annotates genes with predicted seed match counts and allows researchers to compare expression changes between genes with and without seed matches. The paper also used publicly available RNA-seq data from siRNA experiments to demonstrate detection of seed-mediated off-target patterns.
Results
Figure 1 in the paper shows the full SeedMatchR workflow and example applications. The figure includes siRNA seed definition, required inputs and outputs, and ECDF-based detection of seed-mediated off-target effects.
In Figure 1D, SeedMatchR detected a significant shift in the distribution of log2 fold changes for genes with a seed match compared with genes without seed matches. The reported Kolmogorov-Smirnov test result was Dstat = 0.138674 with P-value = 7.74 × 10−8.
Figure 1E showed that a glycol nucleic acid modification at the seed region reduced the off-target signal. The reported result was Dstat = 0.049007 with P-value = 8.239 × 10−2. This contrast shows how RNA-seq and seed-aware bioinformatics can help compare siRNA designs by off-target behavior, not only by target knockdown.
Figure 1 from SeedMatchR illustrates how siRNA guide sequence, seed definition, differential expression data, and transcript annotations can be integrated to detect seed-mediated off-target effects in RNA-seq experiments.
Conclusion
This case supports the value of pairing siRNA experiments with RNA-seq and dedicated bioinformatics review. For ASO and siRNA research teams, it shows why a useful data package should include differential expression results, candidate-specific annotations, visualizations, and statistical review of off-target-related expression patterns.
Figure 1 is useful for ASO and siRNA research teams because it shows how sequence information, transcript annotation, differential expression, and visualization can be combined into one off-target review workflow.
Related Customer Publications
CD Genomics has supported a wide range of sequencing and bioinformatics projects across genomics, transcriptomics, non-coding RNA, and mechanism-focused research. The publications below are not presented as ASO or siRNA case studies. They are included as related examples of customer research using sequencing or RNA-focused services.
In vivo base editing rescues ADPKD in a humanized mouse model
Journal: Nature Communications
Year: 2025
Relevant Service Connection: RNA-seq-supported molecular validation in a gene-therapy-adjacent research setting
Autophagic stress activates distinct compensatory secretory pathways in neurons
Journal: Proceedings of the National Academy of Sciences
Year: 2025
Relevant Service Connection: Small RNA sequencing and stress-response biology
Targeting the CLK2/SRSF9 splicing axis in prostate cancer leads to decreased tumorigenesis
Journal: Molecular Oncology
Year: 2024
Relevant Service Connection: RNA-seq-supported drug mechanism and splicing-axis research
Platelets and inflammation—insights from platelet non-coding RNA content and regulation
Journal: Cardiovascular Research
Year: 2025
Relevant Service Connection: Non-coding RNA and inflammation-related molecular profiling
Disclaimer
For Research Use Only. The services described on this page are intended to support scientific research and development studies. They are not intended for diagnostic use, patient management, treatment guidance, or direct-to-consumer genetic testing.
